NCT06441747
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06441747
Title Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Australasian Gastro-Intestinal Trials Group
Indications
Therapies
Age Groups: senior | adult
Covered Countries AUS

Facility Status City State Zip Country Details
Chris O'Brien Lifehouse RECRUITING Camperdown New South Wales 2050 Australia Details
Monash Medical Centre NOT_YET_RECRUITING Clayton New South Wales 3168 Australia Details
Royal North Shore Hospital NOT_YET_RECRUITING St Leonards New South Wales 2065 Australia Details
Westmead Hospital NOT_YET_RECRUITING Westmead New South Wales 2145 Australia Details
Wollongong Hospital NOT_YET_RECRUITING Wollongong New South Wales 2500 Australia Details
Princess Alexandra Hospital RECRUITING Woolloongabba Queensland 4102 Australia Details
Flinders Medical Centre RECRUITING Bedford Park South Australia Australia Details
Austin Health RECRUITING Melbourne Victoria 3084 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field